PRLD Share Price Performance
US$3.43
2.72 (384.53%)
14.3% overvalued intrinsic discount
US$3.00
Fair Value
Price US$3.43
AnalystLowTarget US$3.00
AnalystHighTarget US$5.00
Fair ValueUS$3.00
Share Pricen/a
Prelude Therapeutics Incorporated Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 8 Fair Values set on narratives written by author
PRLD Community Narratives
AN
Fair Value US$3 14.3% overvalued intrinsic discount
Future Returns Will Depend On JAK2 Program Validation And Incyte Milestones
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$5 31.4% undervalued intrinsic discount
Future Oncology Platform Will Be Transformed By Targeted Degraders And JAK2-Focused Precision Therapies
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Future Returns Will Depend On JAK2 Program Validation And Incyte Milestones
Catalysts About Prelude Therapeutics Prelude Therapeutics is a clinical stage oncology company focused on discovering and developing precision cancer medicines. What are the underlying business or industry changes driving this perspective?Read more
5
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$3
14.3% overvalued intrinsic discount
Fair Value
Profit Margin
56.74%
Future PE
3.16x
Price in 2029
US$3.7
Future Oncology Platform Will Be Transformed By Targeted Degraders And JAK2-Focused Precision Therapies
Catalysts About Prelude Therapeutics Prelude Therapeutics is a clinical stage oncology company focused on discovering and developing precision cancer medicines. What are the underlying business or industry changes driving this perspective?Read more
4
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$5
31.4% undervalued intrinsic discount
Fair Value
Profit Margin
55.6%
Future PE
5.59x
Price in 2029
US$6.16
Trending Discussion
Recently Updated Narratives
AN
Future Returns Will Depend On JAK2 Program Validation And Incyte Milestones
Fair Value: US$3 14.3% overvalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Future Oncology Platform Will Be Transformed By Targeted Degraders And JAK2-Focused Precision Therapies
Fair Value: US$5 31.4% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Prelude Therapeutics Incorporated Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -1.21
- 100.00%
- -819.59%
- 0%
About PRLD
- Founded
- 2016
- Employees
- 79
- CEO
- WebsiteView website
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
